HBK Sorce Advisory LLC Takes Position in Becton Dickinson and Co (BDX)

HBK Sorce Advisory LLC bought a new stake in Becton Dickinson and Co (NYSE:BDX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,961 shares of the medical instruments supplier’s stock, valued at approximately $848,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Legacy Advisors LLC lifted its stake in shares of Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 490 shares during the period. Amica Retiree Medical Trust lifted its stake in Becton Dickinson and by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares during the period. Almanack Investment Partners LLC. bought a new position in Becton Dickinson and during the fourth quarter worth about $109,000. FTB Advisors Inc. lifted its stake in Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares during the period. Finally, Advisors Preferred LLC bought a new position in Becton Dickinson and during the fourth quarter worth about $126,000. Institutional investors and hedge funds own 83.40% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NYSE:BDX traded down $4.63 during trading on Friday, reaching $215.50. The stock had a trading volume of 1,320,605 shares, compared to its average volume of 1,153,007. Becton Dickinson and Co has a 52 week low of $175.66 and a 52 week high of $248.39. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $57,375.15, a P/E ratio of 22.73, a price-to-earnings-growth ratio of 1.56 and a beta of 1.15.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the previous year, the company posted $2.33 earnings per share. Becton Dickinson and’s quarterly revenue was up 5.4% compared to the same quarter last year. analysts forecast that Becton Dickinson and Co will post 10.95 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, March 30th. Investors of record on Friday, March 9th were issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.39%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

A number of research analysts have commented on BDX shares. Zacks Investment Research cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Morgan Stanley raised their price target on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. KeyCorp started coverage on shares of Becton Dickinson and in a research note on Friday, January 5th. They set an “overweight” rating and a $260.00 price target for the company. Bank of America restated a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research note on Friday, January 19th. Finally, Citigroup upgraded shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a research note on Friday, January 5th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $240.53.

In related news, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP James W. Borzi sold 4,048 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $224.98, for a total transaction of $910,719.04. Following the completion of the sale, the executive vice president now directly owns 5,334 shares of the company’s stock, valued at approximately $1,200,043.32. The disclosure for this sale can be found here. In the last three months, insiders sold 281,108 shares of company stock valued at $61,321,396. 1.00% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/hbk-sorce-advisory-llc-purchases-shares-of-3961-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply